Table 5.
Multivariable Cox Regression Model on Time to First Nonatherosclerotic Event, Intention‐to‐Treat Analysis
| Variable | Hazard Ratio (95% CI) | P Value |
|---|---|---|
| Treatment (cinacalcet/placebo) | 0.84 (0.73 to 0.96) | 0.009 |
| Age | 1.03 (1.03 to 1.04) | <0.001 |
| Geographical region (ref, United States) | <0.001 | |
| Russia | 0.57 (0.40 to 0.82) | |
| Latin America | 0.76 (0.59 to 0.97) | |
| Europe | 0.49 (0.39 to 0.61) | |
| Canada | 0.67 (0.48 to 0.93) | |
| Australia | 0.69 (0.49 to 0.99) | |
| Race (ref, white) | 0.090 | |
| Black | 0.86 (0.71 to 1.05) | |
| Other | 0.81 (0.66 to 0.99) | |
| History of coronary artery disease | 1.28 (1.08 to 1.51) | 0.004 |
| History of cardiac arrhythmia | 1.18 (0.97 to 1.43) | 0.100 |
| History of diabetes | 1.54 (1.32 to 1.80) | <0.001 |
| History of dyslipidemia | 0.87 (0.75 to 1.02) | 0.079 |
| History of heart failure | 1.35 (1.16 to 1.57) | 0.000 |
| Other cardiac disease history (valvular heart disease, angina) | 1.35 (1.15 to 1.58) | 0.000 |
| History of peripheral vascular disease | 1.21 (1.03 to 1.44) | 0.025 |
| Tobacco use (ref, never) | <0.001 | |
| Current | 1.66 (1.38 to 2.00) | |
| Former | 1.14 (0.98 to 1.33) | |
| Type of vascular access (ref, natural fistula) | 0.090 | |
| Permanent catheter | 0.99 (0.80 to 1.22) | |
| Other | 1.13 (0.73 to 1.74) | |
| Graft | 1.25 (1.04 to 1.49) | |
| Baseline aspirin use | 0.98 (0.85 to 1.14) | 0.809 |
| Baseline amiodarone use | 1.10 (0.75 to 1.62) | 0.617 |
| Baseline proton pump inhibitor use | 1.08 (0.94 to 1.25) | 0.285 |
| Baseline warfarin use | 0.97 (0.75 to 1.25) | 0.794 |
| Baseline serum cholesterol per 10 mg/dL increase | 0.98 (0.97 to 1.00) | 0.058 |
| Baseline serum HDL per 10 mg/dL increase | 1.04 (0.99 to 1.08) | 0.112 |
| Baseline serum albumin, g/dL | 0.68 (0.56 to 0.82) | <0.001 |
| Diastolic blood pressure per 10 mm Hg increase | 1.09 (1.04 to 1.15) | 0.001 |
Variables were selected by backward elimination. The baseline variables sex, hemoglobin, corrected serum calcium, serum phosphorus, and calcium phosphorus product were not included in the regression model due to lack of statistically significant independent association with the end point at α=0.25 in a separate model for each. Baseline use of aspirin, amiodarone, proton pump inhibitor, or warfarin was added to the final model. P=0.359 for interaction of treatment with age. HDL indicates high‐density lipoprotein.